The complement system can be activated in a number of ways, and improper complement activation can lead to diseases such as neuromyelitis optica. Currently, anti-C5 therapies are the approved treatment for reducing disease caused by the complement system, but which of the following therapies could also, in theory, reduce the activation of complement on self-tissues and cells? anti-IL-1 monoclonal antibodies anti-IL-5 monoclonal antibodies anti-IL-6R monoclonal antibodies anti-CD20 monoclonal antibodies